Ad
Tuesday, 10 April 2018
New GSK shingles vaccine off to strong start in key U.S. market
LONDON (Reuters) - GlaxoSmithKline's new shingles vaccine - a priority product as the company strives to improve its drugs line-up - has won more than 90 percent U.S. market share just five months after its launch, prescription-tracking data show.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment